Russia to allow imported drugs that have not undergone clinical trials in the country

25 October 2018


The Russian government plans to provide access to imported drugs that have not undergone clinical trials within Russia, according to recent statements by some senior officials of the Russian Ministry of Health, reports The Pharma Letter's local correspondent.

This will apply to drugs from countries of the European Union, as well as the USA and Japan and will be part of the existing roadmap "Development of Competition in Public Health," which has been recently approved by the Russian government, The Pharma Letter’s local correspondent reports.

A spokesman for Russian Minister of Health Veronika Skvortsova said this measure will provide domestic patients with better access to new drugs.

It is planned that such drugs will be labeled with a warning that the drug has not undergone clinical research in the Russian Federation.

Currently, the launch of a new drug into the Russian market takes up to five years, of which up to three years is taken up by domestic clinical trials. However, this situation is expected to change shortly.

Planned liberalization will not affect all the new drugs supplied to the Russian market, but primarily those the production of which analogues has not established in the country. It is planned that final principles of drug selection should be worked out by the end of the current year.

Currently the list of the most demanded drugs among Russian patients includes anti-cancer drug and drugs against epilepsy, as well as orphan drugs for the treatment of rare diseases.

According to the Ministry of Health, implementation of the new initiative will be started by the end of the current year.


Previous publication Next publication

Media Center

  • 31 October 2018

    Scientists unveiled a more effective approach for assessing drug response

    Scientists from Eli Lilly and Company, the Icahn School of Medicine at Mount Sinai (New York, USA) and Sema4 (Stamford, USA) released results from a proof-of-concept study demonstrating that patient-derived cells offer a more effective approach for assessing drug response than conventional methods.

  • 30 October 2018

    Researchers developed an AI approach to identify antibiotic resistance genes

    Researchers at the University of California San Diego (USA) have developed an approach that uses machine learning to identify and predict which genes make infectious bacteria resistant to antibiotics. The approach was tested on strains of Mycobacterium tuberculosis – the bacteria that cause tuberculosis (TB) in humans. It identified 33 known and 24 new antibiotic resistance genes in these bacteria.

  • 29 October 2018

    Expanding the reach of gene editing with a new CRISPR enzyme

    The CRISPR-Cas9 gene editing system has been widely studied because of its potential therapeutic applications, but limitations in the number of locations on the genome it can target remain a major drawback. Now scientists at the Massachusetts Institute of Technology have identified a new Cas9 enzyme that they say can help CRISPR reach more gene mutations.

  • 26 October 2018

    Biotech Backed by Bain, Pfizer loads prime CNS assets into new biotech

    Pfizer has followed through on its pledge to divest a hunk of its neuroscience R&D, spinning several programs into a new company called Cerevel Therapeutics backed by $350 million in venture funding. Pfizer is contributing a trio of clinical-stage drug candidates—including a Parkinson’s therapy due to start phase 3 testing next year—plus a clutch of earlier-stage programs, while Bain Capital and affiliates stumped up the initial funding.

Read more